| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Elucidating the function of leukemic stem cell, that generates leukemic blasts and retains self-renewal potency, is required for characterization of leukemia and improving efficiency of chemo-therapy. The aim of this study is identification and characterization of the leukemic stem cell sustaining Down-syndrome associated acute megakaryoblastic leukemia (DS-AMKL). Human DS-AMKL- or hematopoietic stem cell-xenograft mice enabled to provide and analyze human leukemic cells and healthy hematopoietic stem cells stably. Utilizing this system, CD34 positive and Hoechst high-stained fraction was identified as a candidate fraction residing leukemic stem cell in this DS-AMKL. This information provides useful guideline to isolate the fraction with high concentration of leukemic stem cells.
|
